当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
The Lancet ( IF 168.9 ) Pub Date : 2017-08-01 , DOI: 10.1016/s2213-8587(17)30182-1
David Z I Cherney , Bernard Zinman , Silvio E Inzucchi , Audrey Koitka-Weber , Michaela Mattheus , Maximilian von Eynatten , Christoph Wanner

In a pooled analysis of short-term trials, short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria. In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease, according to patients' baseline albuminuria status.

中文翻译:

依帕格列净对2型糖尿病和已确定的心血管疾病患者尿白蛋白/肌酐比值的影响:一项来自EMPA-REG OUTCOME随机安慰剂对照试验的探索性分析。

在一项短期试验的汇总分析中,使用钠-葡萄糖共转运蛋白2(SGLT2)抑制剂empagliflozin进行的短期治疗可降低2型糖尿病和普遍性白蛋白尿患者的白蛋白尿。在对EMPA-REG OUTCOME试验的探索性分析中,我们根据患者的基线白蛋白尿状况报告了依帕列净对2型糖尿病和已确定的心血管疾病患者的蛋白尿的短期和长期影响。
更新日期:2017-08-10
down
wechat
bug